HelioLiver LDT now available to order through Quest Diagnostics
Helio Genomics Our Story Technology Research Our Team Blog & Interviews News & Media HelioLiver LDT Overview The Science For Providers The HelioLiver Test Clinical Evidence FAQ For Patients Overview Early Detection Testing with HelioLiver Resources FAQ Contact
Scientists working with genomic sequencing data in a research laboratory
Our Technology

The Helio Solution to Early Cancer Detection

We harness the power of artificial intelligence and machine learning to predict the presence of cancer earlier.

10+ Years of Research AI-Powered Detection Stage I Detection Focus
Multi-Modal × Multi-Omics

Multi-Modal × Multi-Omics Integration

Helio's tests generate deeper, richer biological insights using machine-learning technology that combines years of multi-modal and multi-omics research. Over the past 10 years, our team of scientists has used artificial intelligence and machine learning to identify unique, proprietary DNA signatures that predict the presence of cancer as early as Stage I. We combine these DNA signatures with protein biomarkers to develop multi-analyte blood tests with greater sensitivity and specificity than current screening methods.

Our research continues to add more data types and features to our bioinformatics pipeline, allowing us to capture a wider array of signals and continuously improve our AI.

Helio AI Engine
Multi-analyte signal fusion
DNA Methylation
Protein Biomarkers
Genomic Signals
Clinical Data
Machine Learning
Sequencing Results
The ECLIPSE™ Platform

Optimising DNA Methylation Capture with ECLIPSE™

Helio Genomics has developed a proprietary platform called ECLIPSE, which enables accurate, efficient detection of cell-free DNA methylation patterns from blood — identifying the unique biomarkers that signal cancer, using next-generation sequencing technology.

1

cfDNA Extraction

Cell-free DNA is extracted from a blood sample.

2

Library Preparation and Enzymatic Conversion

The sample is prepared and enzymatically converted for analysis.

3

Hybridisation and Capture

Target methylation regions are captured.

4

Pooling and Sequencing

Samples are pooled and sequenced using next-generation sequencing.

Video

Watch the Video to Learn More

Nature®
Peer-Reviewed Publication
Peer-Reviewed Science

Identifying epigenetic modifications leads to earlier cancer detection.

Published in Nature.

Read the Article
What's Next

What's Next for Helio?

With HelioLiver developed and commercially available, Helio's development pipeline includes HelioLiver 2.0 — the next generation of HelioLiver — as well as minimal residual disease and treatment-monitoring tests for HCC. Our AI-based methods for early cancer detection are built on a robust research and development program, leveraging an extensive patient sample bank for validation.

Indication Product
Biomarker Discovery Algorithm Training Case Control Validation Prospective Validation
Hepatocellular Carcinoma (HCC) Surveillance Test HelioLiver
Hepatocellular Carcinoma (HCC) Surveillance Test HelioLiver 2.0
HCC MRD HL-MRD1
HCC Monitoring HL-MONITOR1